What's new in Interventional Cardiology

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Women have long been underrepresented in TAVR trials. This article explores the DEDICATE trial’s sex-specific outcomes after TAVI and SAVR, revealing differences in early stroke risk, procedural challenges, and one-year survival in men and women with aortic stenosis.

Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).

An 85-year-old man presented in cardiogenic shock with torrential aortic regurgitation after prior surgical and TAVI valve-in-valve procedures. With high coronary obstruction risk, urgent CT assessment and in-silico simulations guided a rapid redo TAVI-in-TAVI-in-valve implantation, demonstrating that CT-assisted emergency redo-TAVI is feasible and lifesaving in high-risk...

Ali Nazmi Calik provides his take on the results of the OPTIMAL trial presented by Luca Testa at ACC.26 in New Orleans.

Alex Sticchi interviews Erwan Donal on the 2-year outcomes of the TRI-FR randomised trial evaluating transcatheter tricuspid edge-to-edge repair (T-TEER) versus medical therapy alone, as presented at ACC.26 in New Orleans.

Aaysha Cader interviews Divaka Perera on the CHIP-BCIS3 randomised trial, which evaluated whether elective left ventricular (LV) unloading during high-risk PCI improves outcomes in patients with severe LV dysfunction, extensive coronary disease, and complex procedures, as presented at ACC.26 in New Orleans.

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.

Catheter-based left atrial appendage closure (LAAC) is widely used as an alternative to oral anticoagulation in atrial fibrillation. But how does it compare with best medical therapy in patients at high risk of both stroke and bleeding? The CLOSURE-AF trial provides new data to inform this...